141 related articles for article (PubMed ID: 26841296)
1. L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
Alshiekh-Nasany R; Douer D
Acta Haematol; 2016; 135(4):208-10. PubMed ID: 26841296
[TBL] [Abstract][Full Text] [Related]
2. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
3. Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia.
Trang E; Ngo D; Chen J; Aldoss I; Salhotra A; Pullarkat V
Leuk Lymphoma; 2020 Dec; 61(13):3161-3164. PubMed ID: 32787645
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
5. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
6. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
7. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
8. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.
Rausch CR; Paul S; Marx KR; Jabbour E; Pemmaraju N; Ferrajoli A; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e191-e195. PubMed ID: 29550108
[No Abstract] [Full Text] [Related]
9. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Schulte RR; Madiwale MV; Flower A; Hochberg J; Burke MJ; McNeer JL; DuVall A; Bleyer A
Leuk Lymphoma; 2018 Oct; 59(10):2360-2368. PubMed ID: 29431566
[TBL] [Abstract][Full Text] [Related]
10. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the Effectiveness and Safety of Combined Chemotherapy with PEG-Asp for Treatment of ALL and T-NHL Patients].
Xu Y; Wang J; Yang N; Bai J; Zhang PY; Gu LF; Lei B; Liu J; Wang FX; Huang BQ; Zhang WG; He AL; Cao XM; Chen YX; Ma XR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):405-10. PubMed ID: 27151000
[TBL] [Abstract][Full Text] [Related]
14. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
15. Pegasparaginase: where do we stand?
Zeidan A; Wang ES; Wetzler M
Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697
[TBL] [Abstract][Full Text] [Related]
16. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Buie LW; Moore J; van Deventer H
Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
[TBL] [Abstract][Full Text] [Related]
17. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
18. L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity.
Arora S; Klair J; Bellizzi AM; Tanaka T
ACG Case Rep J; 2019 Aug; 6(8):e00194. PubMed ID: 31737724
[TBL] [Abstract][Full Text] [Related]
19. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
Lussana F; Minetto P; Ferrara F; Chiaretti S; Specchia G; Bassan R
BMC Cancer; 2020 Oct; 20(1):956. PubMed ID: 33008391
[TBL] [Abstract][Full Text] [Related]
20. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Blackman A; Boutin A; Shimanovsky A; Baker WJ; Forcello N
J Oncol Pharm Pract; 2018 Jul; 24(5):393-397. PubMed ID: 28523950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
